Cargando…
Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration – a MACUSTAR study report
BACKGROUND/AIMS: To further validate the Vision Impairment in Low Luminance (VILL) questionnaire, which captures visual functioning and vision-related quality of life (VRQoL) under low luminance, low-contrast conditions relevant to age-related macular degeneration (AMD). METHODS: The VILL was transl...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359508/ https://www.ncbi.nlm.nih.gov/pubmed/35354561 http://dx.doi.org/10.1136/bjophthalmol-2021-320848 |
_version_ | 1785075898712588288 |
---|---|
author | Terheyden, Jan Henrik Pondorfer, Susanne G Behning, Charlotte Berger, Moritz Carlton, Jill Rowen, Donna Bouchet, Christine Poor, Stephen Luhmann, Ulrich F O Leal, Sergio Holz, Frank G Butt, Thomas Brazier, John E Finger, Robert P |
author_facet | Terheyden, Jan Henrik Pondorfer, Susanne G Behning, Charlotte Berger, Moritz Carlton, Jill Rowen, Donna Bouchet, Christine Poor, Stephen Luhmann, Ulrich F O Leal, Sergio Holz, Frank G Butt, Thomas Brazier, John E Finger, Robert P |
author_sort | Terheyden, Jan Henrik |
collection | PubMed |
description | BACKGROUND/AIMS: To further validate the Vision Impairment in Low Luminance (VILL) questionnaire, which captures visual functioning and vision-related quality of life (VRQoL) under low luminance, low-contrast conditions relevant to age-related macular degeneration (AMD). METHODS: The VILL was translated from German into English (UK), Danish, Dutch, French, Italian and Portuguese. Rasch analysis was used to assess psychometric characteristics of 716 participants (65% female, mean age 72±7 years, 82% intermediate AMD) from the baseline visit of the MACUSTAR study. In a subset of participants (n=301), test–retest reliability (intraclass correlation coefficient (ICC) and coefficient of repeatability (CoR)) and construct validity were assessed. RESULTS: Four items were removed from the VILL with 37 items due to misfit. The resulting Vision Impairment in Low Luminance with 33 items (VILL-33) has three subscales with no disordered thresholds and no misfitting items. No differential item functioning and no multidimensionality were observed. Person reliability and person separation index were 0.91 and 3.27 for the Vision Impairment in Low Luminance Reading Subscale (VILL-R), 0.87 and 2.58 for the Vision Impairment in Low Luminance Mobility Subscale (VILL-M), and 0.78 and 1.90 for the Vision Impairment in Low Luminance Emotional Subscale (VILL-E). ICC and CoR were 0.92 and 1.9 for VILL-R, 0.93 and 1.8 for VILL-M and 0.82 and 5.0 for VILL-E. Reported VRQoL decreased with advanced AMD stage (p<0.0001) and was lower in the intermediate AMD group than in the no AMD group (p≤0.0053). CONCLUSION: The VILL is a psychometrically sound patient-reported outcome instrument, and the results further support its reliability and validity across all AMD stages. We recommend the shortened version of the questionnaire with three subscales (VILL-33) for future use. TRIAL REGISTRATION NUMBER: NCT03349801. |
format | Online Article Text |
id | pubmed-10359508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-103595082023-07-22 Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration – a MACUSTAR study report Terheyden, Jan Henrik Pondorfer, Susanne G Behning, Charlotte Berger, Moritz Carlton, Jill Rowen, Donna Bouchet, Christine Poor, Stephen Luhmann, Ulrich F O Leal, Sergio Holz, Frank G Butt, Thomas Brazier, John E Finger, Robert P Br J Ophthalmol Clinical Science BACKGROUND/AIMS: To further validate the Vision Impairment in Low Luminance (VILL) questionnaire, which captures visual functioning and vision-related quality of life (VRQoL) under low luminance, low-contrast conditions relevant to age-related macular degeneration (AMD). METHODS: The VILL was translated from German into English (UK), Danish, Dutch, French, Italian and Portuguese. Rasch analysis was used to assess psychometric characteristics of 716 participants (65% female, mean age 72±7 years, 82% intermediate AMD) from the baseline visit of the MACUSTAR study. In a subset of participants (n=301), test–retest reliability (intraclass correlation coefficient (ICC) and coefficient of repeatability (CoR)) and construct validity were assessed. RESULTS: Four items were removed from the VILL with 37 items due to misfit. The resulting Vision Impairment in Low Luminance with 33 items (VILL-33) has three subscales with no disordered thresholds and no misfitting items. No differential item functioning and no multidimensionality were observed. Person reliability and person separation index were 0.91 and 3.27 for the Vision Impairment in Low Luminance Reading Subscale (VILL-R), 0.87 and 2.58 for the Vision Impairment in Low Luminance Mobility Subscale (VILL-M), and 0.78 and 1.90 for the Vision Impairment in Low Luminance Emotional Subscale (VILL-E). ICC and CoR were 0.92 and 1.9 for VILL-R, 0.93 and 1.8 for VILL-M and 0.82 and 5.0 for VILL-E. Reported VRQoL decreased with advanced AMD stage (p<0.0001) and was lower in the intermediate AMD group than in the no AMD group (p≤0.0053). CONCLUSION: The VILL is a psychometrically sound patient-reported outcome instrument, and the results further support its reliability and validity across all AMD stages. We recommend the shortened version of the questionnaire with three subscales (VILL-33) for future use. TRIAL REGISTRATION NUMBER: NCT03349801. BMJ Publishing Group 2023-08 2022-03-30 /pmc/articles/PMC10359508/ /pubmed/35354561 http://dx.doi.org/10.1136/bjophthalmol-2021-320848 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Science Terheyden, Jan Henrik Pondorfer, Susanne G Behning, Charlotte Berger, Moritz Carlton, Jill Rowen, Donna Bouchet, Christine Poor, Stephen Luhmann, Ulrich F O Leal, Sergio Holz, Frank G Butt, Thomas Brazier, John E Finger, Robert P Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration – a MACUSTAR study report |
title | Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration – a MACUSTAR study report |
title_full | Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration – a MACUSTAR study report |
title_fullStr | Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration – a MACUSTAR study report |
title_full_unstemmed | Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration – a MACUSTAR study report |
title_short | Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration – a MACUSTAR study report |
title_sort | disease-specific assessment of vision impairment in low luminance in age-related macular degeneration – a macustar study report |
topic | Clinical Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359508/ https://www.ncbi.nlm.nih.gov/pubmed/35354561 http://dx.doi.org/10.1136/bjophthalmol-2021-320848 |
work_keys_str_mv | AT terheydenjanhenrik diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport AT pondorfersusanneg diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport AT behningcharlotte diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport AT bergermoritz diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport AT carltonjill diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport AT rowendonna diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport AT bouchetchristine diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport AT poorstephen diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport AT luhmannulrichfo diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport AT lealsergio diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport AT holzfrankg diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport AT buttthomas diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport AT brazierjohne diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport AT fingerrobertp diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport AT diseasespecificassessmentofvisionimpairmentinlowluminanceinagerelatedmaculardegenerationamacustarstudyreport |